Clinical and spirometric alterations in Duchenne muscular dystrophy

被引:0
|
作者
Andrada, LE [1 ]
DeVito, EL [1 ]
机构
[1] UNIV BUENOS AIRES, FAC MED, INST INVEST MED ALFREDO LANARI, RA-1053 BUENOS AIRES, DF, ARGENTINA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 36 patients with Duchenne muscular dystrophy we studied the growth pattern, the type and severity of the spirometric abnormalities, the evolution of the Motor Functional Class (MFC), the infectious complications and treatments. Their age ranged from 6 to 19 years and the MFC was from 1 to 9. Regarding height, up to 12 years we verified a slope of 5.69 +/- 0.58 cm/year (r 0.872 p < 0.001) and a posterior detention was observed. Of the 36 patients, 24 were below the percentile 5. The restrictive disorder prevailed. The forced Vital capacity (FVC) expressed in % of the theoretical Value showed a lineal fall with age, with a negative correlation (r 0.51, p < 0.01) of - 3.5 +/- 0.83%/year. The deterioration of the MFC was marked starting from 6 years; with a slope of 0.84 +/- 0,14 points between 6 to 12 years (r 0.73 p x 0.001). Up to 14 years, the slope was 0.212 +/- 0.084 (r 0.49, p < 0,05). Patients older than 14 years had reached a greater CFM of 7; starting from this MFC a progressive fall of the VC was observed with a slope of - 15.29 +/- 3.39% of CVF/CF (r 0.56, p < 0.001). Nine patients with respiratory infections were documented. Four were pneumonia and 3 of them required mechanical ventilation and died. Only 50% of the patients accepted rehabilitating treatment. Four patients accepted surgery of the alterations of the feet while the patients with deformation of the column underwent spinal stabilization.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 50 条
  • [21] Duchenne muscular dystrophy
    Lankester, Benedict J. A.
    Whitehouse, Michael R.
    Gargan, Martin F.
    CURRENT ORTHOPAEDICS, 2007, 21 (04): : 298 - 300
  • [22] Duchenne muscular dystrophy
    Chamberlain, Jeffrey S.
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1991, 1 (01) : 11 - 14
  • [23] Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy
    Tsabari, Reuven
    Simchovitz, Elana
    Lavi, Eran
    Eliav, Osnat
    Avrahami, Ran
    Ben-Sasson, Shmuel
    Dor, Talya
    NEUROMUSCULAR DISORDERS, 2021, 31 (09) : 803 - 813
  • [24] Clinical management of Duchenne muscular dystrophy: the state of the art
    Sonia Messina
    Gian Luca Vita
    Neurological Sciences, 2018, 39 : 1837 - 1845
  • [25] Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
    Namgoong, John Hyun
    Bertoni, Carmen
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2016, 6 : 37 - 48
  • [26] Epidemiological evaluation of clinical history in Duchenne muscular dystrophy
    Martinelli, F
    Felisari, G
    Turconi, A
    Comi, GP
    Robotti, M
    Ausenda, CD
    Scarlato, G
    Bresolin, N
    NEUROLOGY, 1997, 48 (03) : 5040 - 5040
  • [27] Improving clinical trial design for Duchenne muscular dystrophy
    Luciano Merlini
    Patrizia Sabatelli
    BMC Neurology, 15
  • [28] Quantitative MRI and MRS detect alterations in muscle quality in both congenital muscular dystrophy and Duchenne muscular dystrophy
    Willcocks, R.
    Triplett, W.
    Lott, D.
    Forbes, S.
    Dastgir, J.
    Boennemann, C.
    Vandenbome, K.
    Walter, G.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S296 - S296
  • [29] Clinical management of Duchenne muscular dystrophy: the state of the art
    Messina, Sonia
    Vita, Gian Luca
    NEUROLOGICAL SCIENCES, 2018, 39 (11) : 1837 - 1845
  • [30] Duchenne muscular dystrophy: clinical trials and emerging tribulations
    Shieh, Perry B.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (05) : 542 - 546